dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Terviseamet
Sissetulev dokumentAvalik

Infokiri

Terviseamet · 27. jaanuar 2025
Viit
7-8/25/706-1
Registreeritud
27. jaanuar 2025
Dokumendi liik
Sissetulev dokument
Adressaat
Politsei- ja Piirivalveamet
Saabumis/saatmisviis
e-post
Funktsioon
7 Kriisireguleerimine
Sari
7-8 Kirjavahetus kriisireguleerimist puudutavates küsimustes
Toimik
7-8/2025
Vastutaja
Ragnar Vaiknemets (TA, Peadirektori asetäitja (3) vastutusvaldkond)

Failid

  • 📎E-kiri.eml2511 KB
  • 📎Product Security Intelligence Packet_Estonia.pdf1809 KB

Sisu (failidest)

Saatja: "Anneli Kolgo-Makki" <[email protected]> Saaja: "'RA võltsing'" <[email protected]>, "Terviseamet" <[email protected]> Teema: FW: Intelligence package on counterfeit Ozempic and related products (For Estonia) Kuupäev: 2025-01-27 12:18 Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. Tere, Saadan Novo Nordiski poolt välja töötatud infopaketi Ozempicu (ja seotud toodete) kohta teadmiseks ja vajadusel ametite sees edasi jagamiseks, Kui Eestil on antud teemas mingit infot või juhtumeid, palutakse seda jagada ka Interpoliga- Tervitan Anneli Kolgo-Makki Ametiabi grupp Rahvusvahelise ametiabi keskus Rahvusvahelise operatiivinfo büroo Piirivalveosakond Politsei- ja Piirivalveamet Tööstuse 52, 10416 Tallinn Tel 612 3797 (73797) *** AMETIALASEKS KASUTAMISEKS *** Selles e-kirjas sisalduv teave (kaasa arvatud manused) on mõeldud ametialaseks kasutamiseks ning seda võivad kasutada vaid e-kirja adressaadid. E-kirjas sisalduvat teavet ei tohi ilma saatja selgelt väljendatud loata edasi saata ega mistahes viisil kõrvalistele isikutele avaldada. Juhul, kui Te olete saanud käesoleva e-kirja eksituse tõttu, teavitage sellest koheselt saatjat ning kustutage e-kiri oma arvutist. This e-mail and any attachments may contain confidential and privileged information. If you are not the intended recipient, please notify the sender immediately by return e-mail, delete this e-mail and destroy any copies. Any dissemination or use of this information by a person other than the intended recipient is unauthorized and may be illegal From: NG Perry <[email protected]> Sent: Monday, January 27, 2025 7:17 AM To: NCB Tallinn <[email protected]> Cc: OEC-CNET-IGGH <[email protected]> Subject: Intelligence package on counterfeit Ozempic and related products (For Estonia) FROM : IPSG OEC/CNET/IGGH Your ref: New Our ref: 2025/117/OEC/CNET/IGGH/PHPC/PNG Dear NCB colleagues, We hope our email finds you well. In the framework of Operation Pangea XVII and following up from our alerts regarding the increasing trends of counterfeit Ozempic related products globally, we would like to provide you with the attached intelligence package (for Estonia) prepared by the brand owner (Novo Nordisk). We kindly request that you disseminate to the relevant national agency for their monitoring of the situation. Please do not hesitate to contact us should you have any further intelligence or cases for INTERPOL to support your investigations. We look forward to your acknowledgement of this message. Thank you. Best regards, …………………………………………… Perry NG Criminal Intelligence Officer Criminal Networks Public Health and Pharmaceutical Crime INTERPOL Global Complex for Innovation 18 Napier Road, Singapore 258510 Office Phone: +65 6550 3641 [email protected] <mailto:[email protected]> <http://www.interpol.int/> www.interpol.int Background Who is Novo Nordisk? What? Why? Novo Nordisk is a Danish pharmaceutical Attention: Our products have gained world-wide Patient safety: Failure to comply with label or company specialized in diabetes and attention mainly due to weight-loss effects. instruction may cause safety concerns obesity. Counterfeit: This has lead to a surge of counterfeit Dangerous: Counterfeit may cause patient harm products. Low quality Failure to observe cold-chain or storage requirements may cause patient harm Prescription Drugs Cold Chain ONLY (2-8 °C) At-risk Products Wegovy® is approved for Norditropin® is a growth Ozempic® is approved for Rybelsus is approved for treatment of obesity. It is hormone approved for treatment of type 2 diabetes. treatment of type 2 diabetes. injected once weekly. treatment of growth It is injected once weekly. It is taken as a tablet daily. disorders. How to detect counterfeit products? Keep these 3 things in mind: 1. The Sales channel The counterfeits are found on both physical and online channels • Our products should only be sold in legitimate channels. Quality 2. Quality & Origin & The products require professional distribution Origin and cold chain networks. • Our products are only produced by certain factories Contact 3. Contact Novo Nordisk Illicit Novo Nordisk Sales Channels If you have suspicions that counterfeit products are making it to your market, please contact Novo Nordisk. 1. The sales channels WHAT is it about? Sales of semaglutide is increasing online and offline. Sales Sources • Online sales: E-commerce platforms, social media (influencers and illegal sellers) and fake websites • Offline sales: Pharmacies, gyms clubs Illicit HOW to manage it? Sales channels For online sales: • Be aware on social media (TikTok, X (Ex-Twitter), Facebook…) • The fake advertisements redirect to fraudulent websites • Notify us and will take care of the website shutdown For offline sales: • In any case of suspicious NN product sales, contact us. Example Example Ozempic sells online Ozempic Packaging labelled ”Bayer” found in a gym 2. Quality & Origin ORIGIN of the product Our products are only manufactured at the listed sites here • It is counterfeit if products are claimed manufactured elsewhere Check product Trends: quality! • Counterfeit Rybelsus from China • Counterfeit Ozempic from Turkey (on the rise) Quality VERIFICATION of packaging & • Check the dates Origin • Check the batch number below the dates • If the batch number is in this list, be suspicious • Check the general packaging (Novo Nordisk logo, spelling errors, quality of openings…) Example Example Example Fake batch number Incorrect packaging (wrong logo and design) Spelling errors on packaging 3. Contact Novo Nordisk Suspicion? We’re available If you have suspicions that counterfeit products are making it to 24/7! your market, please contact the people below or directly Global Security Contact Novo Nordisk CONTACT PERSONS: Anne DEVAUD Stephen YARDLEY Head Global Product Security (Global) Regional Security Advisor (EMEA) [email protected] [email protected] Jim HENDERSON Renata PEREIRA Director Risk Management (US) Regional Security Advisor (LATAM) [email protected] [email protected] Benedict CHEN Maria Magdalena Korzycka Regional Security Advisor (APAC) Global Product Security Coordinator [email protected] [email protected] 8 8 Our Production Facilities Denmark Brazil Iran Bagsværd, Kalundborg, Hillerød, Monte Claros Tehran Gentofte, Værløse, Måløv Company: Novo Nordisk Brazil Company: NN Pars (PSJ) Company: Novo Nordisk Denmark / Our at-risk products are all manufactured Novo Nordisk A/S USA Algeria from one of these sites. Clayton, Durham, New Blida, Tizi Ouzou • Any product packaging claiming to be France Hampshire Company: Aldaph SPA manufactured elsewhere is counterfeit Chartres Company: Novo Nordisk Inc. / Company: NN France Production Novo Nordisk USA (Clayt.) Russia If you see a company that doesn’t belong Kaluga to the one the side, China Japan Company: Novo Nordisk Russia you can’t trust it and you should directly Tianjin Koriyama report the shipment Company: Novo Nordisk China Company: Novo Nordisk Japan All NN products entering ESTONIA come via these importers and at these ports of entry: Importers and distributors: Port of entry: Producers: • Magnum Medical LTd. • Novo Nordisk A/S • NN France Production • Novo Nordisk Brazil Distributors: • Magnum Medical OU • TAMRO EESTI OU • BALTFARMA OU Products imported, distributed or with a point of entry elsewhere, are counterfeit or diverted If you see a company that doesn’t belong to these lists, you can’t trust it and you need to directly report the shipment Main Batch Numbers at risk • Batch numbers are written on the back of the packaging, below the dates • They are important numbers for us to track our products and their origin Currently, we observe the following batch number at risk: Batch Number Batch do not exist with Product Frequently used Product NN Batch numbers NS6GG22 Rybelsus® MP5B060 Ozempic® FT4A281 Ozempic® NP5E775 Ozempic® NDC7139 Norditropin® MC74746 Norditropin® NS6JT27 Rybelsus® MG5B070 Ozempic® JS7A925 Ozempic® NO6F617 Wegovy® NPSG234 Ozempic® 9F808A Norditropin® • For Ozempic MP5B060, if its 1 mg it is a counterfeit. • For Ozempic NP5E775, batch number does not exist for Ozempic but If you notice a batch number from this exist for Saxenda and sold in Argentina • For Rybelsus NS6JT27, batch number does not exist for Rybelsus but list on a shipment, please be vigilant! exist for NovoEight intended to be sold in Colombia Norditropin® SimpleXx® no more in production worldwide, but still counterfeited CF Batch numbers: FC83012, NDC7139, MC74746, 9F808A Seen recently in Turkey and Greece Abused by bodybuilders Counterfeit Rybelsus example • Rybelsus ranks as the second-most counterfeited Novo Nordisk product • Examine the packaging for spelling mistakes • The provided images highlight the spelling discrepancies identified Counterfeit Saxenda example Modus operandi: • Counterfeiters utilized Apidra SoloStar pens that resemble those of Saxenda. The pens are Sanofi's product, designed for administering rapid-acting insulin. • They substituted the original Apidra labels with counterfeit Saxenda labels • They distributed Alvita needles with the pens, in place of Novo Nordisk’s own Genuine Counterfeit Genuine Saxenda® pen How to differentiate: • Dose Selector extends up to 80 on counterfeit • Label on the pen and carton: Fake Saxenda pen: poor quality and not adhering well • Fake label of poor to the pen quality • Counterfeit needles: ALVITA • Not adhering well to the pen New Modus operandi - NN genuine rapid insulin pen relabeled as Ozempic Counterfeit How to differentiate: • Counterfeiters are using Genuine NN rapid insulin pens and relabelling them as Ozempic • The Ozempic® pen is light blue with a gray injection button, while Fiasp® insulin pens are Genuine Fiasp® pen dark blue with an orange button Counterfeit Ozempic example Modus operandi: • Counterfeiters utilized Apidra SoloStar pens (1) that resemble those of Ozempic (2). The pens are Sanofi's product, designed for administering rapid-acting insulin. • They substituted the original Apidra labels with counterfeit Ozempic labels (3) • They distributed Alvita needles (4) with the pens, in place of Novo Nordisk’s own 1 2 Genuine Counterfeit 3 4 How to differentiate: • Dose Selector extends up to 80 on counterfeit • Label on the pen and carton: poor quality and not adhering well to the pen • Counterfeit needles: ALVITA Fake Ozempic pen: • Fake label of poor quality • Not adhering well to the pen Counterfeit Ozempic example • The fake on the left has a darker blue compared to the more aqua blue for the authentic carton. All the other letterings are a good copy. Counterfeit Ozempic example • The fake in left has a different SKU number compared to the original carton. • The line of the information is misaligned compared to the original, starting from “Refrigerate ..” Counterfeit Ozempic example • The fake is missing a white upside • Poor printing image on the fake and down triangle missing bold wording “day” and “weekly”. Also missing “Lift here” Counterfeit Ozempic example • GTIN is incorrect and the order of the various information. The QR code is black and white where in the legitimate carton is blue and white. Counterfeit Ozempic example • The fake carton was for a “1 mg” but label has “3 ml” The real does not have “3 ml”. • The rest is all different below “For single patient use only”
Allikas: Terviseamet dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel